NewsSignals AI analysis·Benzinga·
Why Is Moderna Stock Sinking Thursday?
Grade Abearish AI signal$MRNASTOCK$MRKSTOCK
Moderna shares fell 25% after an alleged leak of an ESMO 2026 abstract suggested its melanoma vaccine showed lower-than-expected Phase 3 efficacy. The reported abstract details have not been independently confirmed in the supplied context. The development concerns Moderna's oncology vaccine program and was cited as the catalyst for the stock decline.
Bullish strength: 18/100
- Phase 3 has announced a significant improvement in recurrence-free survival
Bearish strength: 82/100
- Leaked data sends stock plunging over 25% in a single day
- Phase 3 efficacy shows 49% less risk reduction than Phase 2
This is automated NewsSignals analysis of third-party reporting, not independent original reporting or investment advice. AI scores are not price predictions.